Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
NCT02851797Phase 3Completed
- Sponsor
- Italfarmaco
- Start
- Jun 2017
- Primary completion
- Feb 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of givinostat in Duchenne muscular dystrophy (DMD), sponsored by Italfarmaco. Started Jun 2017; status: completed.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02851797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02851797.